Technical Analyst Nitin Murarka of SMC Global has maintained 'buy' rating on Ranbaxy stock to achieve an intraday target of Rs 460.

According to him, interested traders can purchase the stock with a stop loss of Rs 445.

The shares of the company, on May 03, closed at Rs 450.55 on the Bombay Stock Exchange (BSE). The share price has seen a 52-week high of Rs 538 and a low of Rs 170 on BSE.

Current EPS is -11.18.

Pfizer and Wyeth have taken legal action against Daiichi Sankyo-owned Ranbaxy Laboratories in a US court for infringing the patent rights of Wyeth's drug, Rapamune.

Wyeth and its new holder, Pfizer, filed a patent-violation case against Ranbaxy and its US divisions, Ranbaxy Pharmaceuticals Inc and Ranbaxy Inc, three days back in US District Court for the District of Delaware.

Ranbaxy Laboratories, on April 28, said that the company is lifting up sales personnel by a third and rolling out scores of novel drugs, which would be the bedrock of its development in the next 25 years.

Ranbaxy employed 1,500 sales executives, the largest recruitment drive in 14 years, and will introduce around 100 branded products by the next few years to regain the top of the pecking order.